Understanding What Drives Cancer to Help Guide Personalized Treatment
Comprehensive DNA + RNA Insights for Precision Oncology
India's only US FDA-cleared genomic profiling assay
Order CellDx-Tissue
India's only US FDA-cleared genomic profiling assay
Order CellDx-TissueCellDx-Tissue is a comprehensive genomic profiling test that provides tumour mutation profiling information intended for use by qualified healthcare professionals in accordance with professional guidelines. By integrating deep genomic sequencing of 517 genes, it enables a detailed understanding of an individuals cancer through its genetic makeup. The test Identifies somatic genomic alterations including single nucleotide variants, insertions and deletions, ERBB2 gene amplification, and fusions in ALK, RET, and ROS1.
Transforming Cancer Care Through Personalized Insights
Discover the genetic changes driving each patient's cancer to support informed clinical decision-making by qualified healthcare professionals.
Understand tumour biology and behavior to guide confident and
informed decisions
Access emerging therapies, medical advances, and relevant
clinical trial opportunities
Results available within 5 business days, minimizing delays in
clinical decision-making
Bringing Precision, Depth, and Clarity to Cancer Care
Integrated DNA and RNA sequencing captures variants, including fusions often missed by DNA-only panels
Reliable performance with low-input tissue samples, delivering consistent results even when sample quality is limited
Harmonized genomic and clinical interpretation combining multiple biomarkers into a unified, decision-ready report
Precision Intelligence for Every Clinical Decision
Identifies US FDA-approved targeted therapies for treatment-naive patients based on their tumor genomic profile
Reveals secondary drivers and alternative pathways when standard therapies are no longer effective
Detects resistance-associated mutations that explain why current treatments have stopped working
Leverages integrated TMB and MSI status to support immunotherapy response assessment
*Offered as part of LDT servicesMatches patients to Phase I–III clinical trials based on their unique molecular profile
Enabling a Deeper Understanding of tumour Biology
Note: Supplementary biomarkers are reported as a professional laboratory services under CLIA-certified environment. These biomarkers have not been cleared by the US FDA.
While DNA testing identifies many genetic changes, some important gene fusions may be missed. RNA-based sequencing improves their detection, helping uncover additional treatment opportunities that might otherwise go unnoticed.
Published literature suggests that integrating RNA-based sequencing can increase detection of actionable fusions by ~20% across solid tumours (1, 2, 3).
FFPE tumour Tissue Or Biopsy Sample Collected For Analysis
High-Quality DNA And RNA Isolation For Comprehensive Profiling
Deep Sequencing Across 517 Genes In a CAP-accredited and CLIA-certified laboratory
Advanced Algorithms identify and classify genomic alteration
Structured reporting of detected genomic alterations and their clinical significance classification